Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study

BMC Anesthesiology

Neha M Doshi⁵  Charles H Cook⁴  Kari L Mount²  Stanislaw P Stawicki⁴  Erin N Frazee¹  Heather A Personett¹  Garrett E Schramm¹  Heather M Arnold³  Claire V Murphy² 

[1] Pharmacy Services, Mayo Clinic, Rochester, MN, USA

[2] Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA

[3] Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, USA

[4] Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

[5] Department of Pharmacy, St. Luke's University Health Network, Bethlehem, PA, USA

关键词: Aerosolized;    Acinetobacter;    Pseudomonas;    Critical illness;    Pneumonia;    Multiple drug resistance;    Colistin;   

Others  :  816662
DOI  :  10.1186/1471-2253-13-45

 received in 2013-04-15, accepted in 2013-11-14,  发布年份 2013

【 摘 要 】

Background

The incidence of multi-drug resistant (MDR) gram-negative (GN) organisms including Pseudomonas and Acinetobacter spp has increased in the last decade, prompting re-evaluation of colistin for the management of these infections. Aerosolized colistin as an adjunct to intravenous therapy is a current option for the management of MDR-GN pneumonia, although data supporting this practice is limited. This study evaluates the efficacy of adjunctive aerosolized colistin in combination with intravenous colistin in critically ill patients with MDR-GN pneumonia.

Methods

A retrospective multi-center cohort analysis comparing critically ill patients with MDR-GN pneumonia who received intravenous colistin (IV) alone or in combination with adjunctive aerosolized colistin (IV/AER) with a primary endpoint of clinical cure at the end of colistin therapy. Secondary endpoints included microbiologic cure, duration of mechanical ventilation, length of stay, and hospital mortality. A post-hoc subgroup analysis was performed for patients with high quality cultures used for diagnosis of MDR-GN pneumonia. Dichotomous data were compared using Fisher’s exact test while the student’s t-test or Mann–Whitney U test were used for continuous variables.

Results

Ninety-five patients met criteria for evaluation with 51 patients receiving IV and 44 receiving IV/AER. Baseline characteristics were similar between the two groups. Twenty patients (39.2%) receiving IV and 24 (54.5%) receiving IV/AER achieved clinical cure (p = 0.135). There was no difference in microbiologic cure rates between the IV and IV/AER colistin groups (40.7vs. 44.4%, p = 0.805). The IV group demonstrated a trend towards higher pneumonia attributable mortality (70.4 vs. 40%, p = 0.055). In the subgroup analysis of patients with high quality respiratory cultures, there was a significantly lower clinical cure rate for those in the IV group as compared to the IV/AER group (31.3 vs. 57.1%, p = 0.033).

Conclusions

Addition of aerosolized colistin to IV colistin may improve clinical cure and mortality for patients with MDR-GN pneumonia. Larger, prospective trials are warranted to confirm the benefit of adjunctive aerosolized colistin in critically ill patients with MDR-GN pneumonia.

【 授权许可】

   
2013 Doshi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Michalopoulos A, Kasiakou SK, Mastora Z, et al.: Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005, 9:R53-R59. BioMed Central Full Text
• [2]Laessig KA: End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia in clinical trials: food and drug administration perspective. Clin Inf Dis 2010, 51:S117-S119.
• [3]Jones ME, Draghi DC, Thornsberry C, et al.: Emerging resistance among bacterial pathogens in the intensive care unit–a European and North American surveillance study (2000–2002). Ann Clin Microbiol Antimicrob 2004, 3:14. BioMed Central Full Text
• [4]Li J, Nationa RL, Turnidge JD, et al.: Colistin: The re-emerging antibiotic for multi-drug resistant gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601.
• [5]Evans ME, Feola DJ, Rapp RP: Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999, 33:960-967.
• [6]Lu Q, Girardi C, Zhang M, et al.: Nebulized and intravenous colistin in experimental pneumonia caused by pseudomonas aeruginosa. Int Care Med 2010, 36:1147-1155.
• [7]Kofteridis DP, Alexopoulou C, Valachis A, et al.: Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case–control study. Clin Infect Dis 2010, 51:1238-1244.
• [8]Korbila IP, Michalopoulos A, Rafailidis PI, et al.: Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010, 16:1230-1236.
• [9]Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health-care associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-322.
• [10]Le F, Ashley ED, Neuhauser MM, et al.: Consensus summary of aerosolized antimicrobial agents: application of guideline criteria: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2010, 30:562-584.
• [11]Michalopoulos A, Papadakis E: Inhaled anti-infective agents: emphasis on colistin. Infection 2010, 38:81-88.
• [12]Kwa ALH, Loh C, Low JGH, et al.: Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Inf Dis 2005, 41:754-757.
• [13]Lin CC, Liu TC, Kuo CF, et al.: Aerosolized colistin for the treatment of multi-drug resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2010, 43:323-331.
• [14]Falagas ME, Siempos II, Rafailidis PI, et al.: Inhaled colistin as monotherapy for multidrug-resistant gram(-) nosocomial pneumonia: a case series. Resp Med 2009, 103:707-713.
• [15]Fagon JY, Chastre J, Domart Y, et al.: Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996, 23:538-542.
• [16]Visscher S, Schruink CA, Melsen WG, et al.: Effects of systemic antibiotic therapy on bacterial persistence in the respiratory tract of mechanically ventilated patients. Int Care Med 2008, 34:692-699.
• [17]Vakil N: Acid inhibition and infections outside the gastrointestinal tract. Am J Gastroenterol 2009, 104:S16-S20.
• [18]Dennesen PJW, van de Ven JAM, Kessels AGH, Ramsay G, Bonten MJM: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001, 163:1371-1375.
• [19]Petrosillo N, Ioannidou E, Falagas ME: Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008, 14:216-227.
• [20]Rynn C, Wootton M, Bowker KE, et al.: In vitro assessment of colistin’s antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999, 5:32-36.
• [21]Timurkaynak F, Can F, Azap OK, et al.: In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006, 27:224-228.